Rubedo skin cream linked to ~2-year drop in epigenetic skin age in small early trial

Mixed · 2Rubedo Life Sciences, a biotech company based in Mountain View, California, says its experimental topical cream lowered the biological age of skin by about two years on average after four weeks of use. 1 2 Left · 1The result comes from 11 people with atopic dermatitis, the most common type of eczema. Wired reports that the estimate used an ageing "clock" designed by another company, Mitra Bio, which analysed the skin samples independently, and that one participant's skin age fell by more than 11 years. 1 Mixed · 2Rubedo also reported a 10% increase in a type of collagen that supports skin structure and lower levels of inflammation-related markers. Fox News notes it is not yet clear what the inflammation changes mean for patients' health. 1 2

Mixed · 2The cream, called RLS-1496, targets senescent ("zombie") cells, which have stopped dividing and can promote inflammation. It aims to switch off the protein GPX4 temporarily, making senescent cells more prone to a regulated form of cell death called ferroptosis. 1 2 Mixed · 2The data were presented at the Aging Research and Drug Discovery meeting in Boston and have not been published as a full peer-reviewed study. The studies were sponsored by Rubedo. 1 2 Mixed · 2In a separate early study in actinic keratosis, a sun-related skin condition, the company reported fewer lesions after about a month. The outlets give different figures: Wired reports a 46% reduction in total lesions among 18 people, while Fox News reports a 49% average reduction among 22 patients. Fox adds that the study was open-label and compared treated with untreated forearms rather than using a placebo. 1 2

Right · 1Rubedo CEO Frederick Beddingfield called the findings significant and said they warrant further investigation. He told Fox News Digital he expects clinical improvements with longer treatment, that the next trial will run for several months, and that FDA approval is three to four years away pending larger trials. He also said irritation is rare and mild and that very few participants show drug in their blood. 2 Mixed · 2Rubedo is also studying the drug for psoriasis and sun-damaged skin and is starting a trial in androgenetic alopecia (hereditary hair loss). Wired reports Beddingfield sees potential in a lower-potency over-the-counter version for general skin ageing that would compete with retinol, and that the company is formulating a pill for age-related metabolic conditions. 1 2 Mixed · 2Outside experts and the reports note limits. Eric Verdin of the Buck Institute said he would be circumspect about what ageing clocks measure, given how many exist. Dermatologist Anthony Rossi of Memorial Sloan Kettering called the work novel but very early-stage, noting that some senescent cells are beneficial, for example in suppressing cancer. Both outlets stress that the measure shows biological markers rather than whether skin looks younger or works better, and that four weeks is too short to know if changes last. 1 2